Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15

NEXT STORY
Beta Bionics Announces Closing of a $63 Million Series B2 Financing, Bringing the Total Series B and B2 Financings to $126 Million
PREV STORY
Cardiac Rhythm Management (CRM) Devices Market to Surpass US$ 19,938.3 Mn by 2026, Boston Scientific Corporation and Medtronic Covers Majority of the Share: Fortune Business Insights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News

AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia

Currently no FDA-approved treatment options for severe preeclampsia, a leading cause of maternal and ...

author_avatar
NASDAQ Market News

Bellerophon Reports 2015 Second Quarter Operational and Financial Results

HAMPTON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage ...

author_avatar
NASDAQ Market News